Biosplice Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Employees: 51

Market Cap: -

Website: http://www.biosplice.com

Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Withdrawn

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: SM04646

First Posted Date: 2018-07-19

Last Posted Date: 2018-10-09

Lead Sponsor: Biosplice Therapeutics, Inc.

Registration Number: NCT03591926

Locations: 🇳🇿
Research Site, Dunedin, New Zealand

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

Phase 1

Completed

Conditions: Tendinopathy

Interventions: Drug: SM04755
Other: White Petrolatum
Other: Sodium lauryl sulfate
Other: Vehicle

First Posted Date: 2018-04-18

Last Posted Date: 2018-04-18

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 223

Registration Number: NCT03502434

Locations: 🇺🇸
Research Site, Lynchburg, Virginia, United States

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Drug: SM08502

First Posted Date: 2017-11-28

Last Posted Date: 2024-08-09

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 82

Registration Number: NCT03355066

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
UT Health San Antonio - Mays Cancer Center, San Antonio, Texas, United States
🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States

and more 16 locations

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

Phase 1

Terminated

Conditions: Degenerative Disc Disease

Interventions: Drug: SM04690

First Posted Date: 2017-08-11

Last Posted Date: 2019-04-23

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 6

Registration Number: NCT03246399

Locations: 🇺🇸
Research Site, Richmond, Virginia, United States

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

Phase 1

Completed

Conditions: Tendinopathy

Interventions: Drug: SM04755
Drug: Vehicle

First Posted Date: 2017-07-25

Last Posted Date: 2017-07-25

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT03229291

Locations: 🇺🇸
Research Site, Tempe, Arizona, United States

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Phase 2

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: SM04690
Other: Sham
Other: Placebo

First Posted Date: 2017-04-21

Last Posted Date: 2021-06-11

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 700

Registration Number: NCT03122860

Locations: 🇺🇸
Research Site, Danville, Virginia, United States

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Completed

Conditions: Osteoarthritis

Interventions: Other: Not applicable (no therapy is administered as part of this study)

First Posted Date: 2016-11-01

Last Posted Date: 2020-04-17

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 703

Registration Number: NCT02951026

Locations: 🇺🇸
Research Site, Charlottesville, Virginia, United States

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: SM04690
Drug: Placebo

First Posted Date: 2015-09-01

Last Posted Date: 2021-03-17

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 455

Registration Number: NCT02536833

Locations: 🇺🇸
Research Site 1, Saint Louis, Missouri, United States
🇺🇸
Research Site 2, Saint Louis, Missouri, United States
🇺🇸
Research Site, Franklin, Wisconsin, United States

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Phase 2

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Topical Vehicle solution
Drug: Topical SM04554 solution

First Posted Date: 2015-07-20

Last Posted Date: 2020-02-17

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 49

Registration Number: NCT02503137

Locations: 🇺🇸
Research Site, Lynchburg, Virginia, United States

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Phase 2

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Vehicle
Drug: SM04554

First Posted Date: 2014-10-27

Last Posted Date: 2020-02-17

Lead Sponsor: Biosplice Therapeutics, Inc.

Target Recruit Count: 310

Registration Number: NCT02275351

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy